Patient has clinically negative lymph nodes. Patient has given written consent. Patient has known allergy to Technetium sulfur colloid or isosulfan blue or other radiopharmaceuticals or truphenylmethane or related compounds. Patient has clinically positive axilliary disease defined as suspicious lymphadenopathy by attending surgeon. Patient is pregnant or nursing female .
Patient is unable to give informed consent due to psychiatric or other mental disorder.
Disease-Related Patients must have a histologic or cytologic confirmed diagnosis of invasive breast cancer. Patients must have evaluable or measurable disease . Patients can have no active second neoplasm other than cervical carcinoma in situ or skin cancer. Patients with prior non-breast malignancies are eligible if they are disease free and are deemed at low risk for recurrence by treating physician. Herceptin or other monoclonal antibody therapy.